Get the Stockscreener App
0.1299
1.59%
-0.0021
Azitra Inc stock is traded at $0.1299, with a volume of 293.59K.
It is down -1.59% in the last 24 hours and down -27.06% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.132
Open:
$0.13
24h Volume:
293.59K
Relative Volume:
0.35
Market Cap:
$7.87M
Revenue:
$7,500
Net Income/Loss:
$-10.96M
P/E Ratio:
-0.0566
EPS:
-2.2943
Net Cash Flow:
$-11.41M
1W Performance:
-1.59%
1M Performance:
-27.06%
6M Performance:
-44.51%
1Y Performance:
-81.98%
1-Day Range:
$0.1262
$0.132
1-Week Range:
$0.1262
$0.1399
52-Week Range:
$0.10
$1.09
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.1299 | 7.87M | 7,500 | -10.96M | -11.41M | -2.2943 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Azitra Inc Stock (AZTR) Latest News
Azitra advances skin rash treatment trial to second cohort By Investing.com - Investing.com Nigeria
Azitra advances skin rash treatment trial to second cohort By Investing.com - Investing.com South Africa
Azitra advances skin rash treatment trial to second cohort - Investing.com
Azitra advances ATR04-484 trial for cancer trea... - Pluang
Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance - PR Newswire
AZTR Forecast — Price Target — Prediction for 2027 - tradingview.com
Azitra Launches At-the-Market Equity Offering Program - The Globe and Mail
Azitra Launches $3.5 Million At-The-Market Stock Offering - Minichart
Form 424B5 Azitra Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 424B5 Azitra Inc For: 28 September By Investing.com - Investing.com South Africa
Azitra Launches $3.5 Million ATM Equity Program With A.G.P./Alliance Global Partners - tradingview.com
A 3% fee on gross proceeds applies if Azitra (AZTR) sells stock under its new agreement. - Stock Titan
AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs - finance.yahoo.com
Enterprise value to EBITDA forward of Azitra Inc – AMEX:AZTR - tradingview.com
Azitra at H.C. Wainwright conference: pipeline leans on skin bacteria - Investing.com
Azitra at H.C. Wainwright conference: pipeline leans on skin bacteria - Investing.com India
Azitra at H.C. Wainwright conference: pipeline leans on skin bacteria By Investing.com - Investing.com Canada
Azitra Inc (AZTR) Ticks Higher: Micro-Cap Biotech Holds Above $0.17 SupportCovered Call Trade - siam.in
Azitra Inc (AZTR) Ticks Higher: Micro-Cap Biotech Holds Above $0.17 SupportOBV Divergence - careplusvn.com
Azitra to Present Corporate Update at Investment Conference - TipRanks
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Azitra's COO to update on clinical progress and new cosmetic protein data at H.C. Wainwright conference. - Pluang
Initial data on a program targeting fine lines and wrinkles will be shared by Azitra - Stock Titan
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Lelezard
AZTR News | AZITRA INC (NYSEARCA:AZTR) - ChartMill
Azitra Inc (AZTR) Holds at $0.17 as Tight Range Between $0.16 Support and $0.18 Resistance PersistsFibonacci Extension - dars.gov.et
Azitra Inc (AZTR) Holds at $0.17 as Tight Range Between $0.16 Support and $0.18 Resistance PersistsSentiment Extreme - careplusvn.com
Azitra Inc (AZTR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Azitra (AZTR) Trading: Closes 13.25% Higher at $0.15; Immediate View: the Near-Term Reference Band Stretches From $0.14 to $0.16 under the Current SnapshotFibonacci Entry Signals - vinanet.vn
Azitra (AZTR) Levels: Finishes 4.81% Higher at $0.13 in the Current Update; Range Check - vinanet.vn
Azitra (AZTR) Levels: Finishes 4.81% Higher at $0.13 in the Current Update; Range Check - siam.in
Azitra Regains NYSE American Listing Compliance Status - The Globe and Mail
Azitra (NYSE:AZTR) Strengthens Market Position After Listing Milestone - Kalkine Media
Branford bioscience firm regains NYSE compliance - Hartford Business Journal
Azitra Regains NYSE American Listing Compliance Status - TipRanks
Azitra regains compliance with NYSE American listing standards - Investing.com
Azitra regains compliance with NYSE American li... - Pluang
Azitra Regains NYSE American Compliance; .BC Indicator to Be Removed - TradingView
Azitra (NYSE: AZTR) wins back listing under new NYSE watch period - Stock Titan
Azitra regains compliance with NYSE American listing standards By Investing.com - Investing.com UK
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards - PR Newswire
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards - Yahoo Finance
Azitra (AZTR) Earnings Comparison: The Bottom-Line Figure Trails Its Comparison in the Available Record; Post-Report Move: Shares Fall 7.61% in the Latest ReadingROA Comparison - vinanet.vn
Azitra (AZTR): Nantahala Capital reports 6.48M-share, 9.99% beneficial stake - Stock Titan
Nantahala Capital Partners (AZTR) discloses 8.40% beneficial stake in Azitra - Stock Titan
Azitra, Inc. (AZTR) stock price, news, quote and history - Yahoo Finance Australia
Azitra Reports Q2 Net Loss of $3.3 Million - Quiver Quantitative
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates - PR Newswire
Azitra (NYSE American: AZTR) posts Q2 2026 loss but lifts equity above NYSE limits - Stock Titan
Azitra, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):